CHI hearing: Some children who had hip surgery may not have reviews until next year, committee told
Developmental dysplasia of the hip is a condition where the ball and socket joint of the hips does not properly form in babies and young children.
On Thursday, the Oireachtas health committee heard from
Children's Health Ireland
(CHI) and the
HSE
in relation to a number of issues that have emerged at the paediatric healthcare provider in recent months.
In recent months, there has been a review into the
use of unauthorised springs in three children with scoliosis
, an
audit on the threshold for hip surgery
and a leaked internal report on 'toxic' work culture and potential misuse of State funding to tackle waiting lists.
READ MORE
A random audit of 147 children who had hip dysplasia surgeries across Temple Street, Crumlin and Cappagh hospitals between 2021 and 2023 was published in recent weeks.
It found 60 per cent of these procedures at Temple Street hospital did not meet the clinical criteria for surgery, with the figure being 79 per cent in Cappagh hospital, raising concerns about the necessity of the surgeries.
Following the audit's publication, the HSE announced there would be an external review panel to allow all families whose children received surgery since 2010 – some 2,200 children – to obtain a second opinion as to whether the surgery their child received was necessary.
Dr Colm Henry, chief clinical officer at the HSE, told politicians that a number of international experts have been identified, and the HSE is 'getting legal opinions to make sure we have robust terms of reference'.
That process will 'take us until September', he said, adding: 'We expect assessment will take us right into the end of this year and into the next year because of the number involved'.
'We'll support parents and their children in any way they need when we're communicating these reports,' he added.
Lucy Nugent, chief executive of CHI, said multidisciplinary team review clinics for the 500 children identified in the audit have started. Only 60 of these patients have been seen so far.
Ms Nugent, who took up the role of chief executive in January, could not say if parents had informed consent around the novel procedure used by surgeons in the two hospitals that the surgeons believed was less invasive and could be performed earlier.
Dr Henry said there was 'no evidence' found during the audit process that the kind of conversations you would expect to take place to explain the risks of surgery had occurred.
In relation to an unpublished report from 2022, which suggested some children may face negative health outcomes due to delays in their care, Ms Nugent said there were 34 children who were identified as 'Crumlin orphans'.
She added that 'to the best of my knowledge' these families were not notified following the completion of the report which highlighted concerns about their care.
Asked why the report, which has since been referred by the HSE to the gardaí, was not reported to law officials earlier, Ms Nugent said the 'unsubstantiated' allegations were investigated at the time, and it was decided 'it did not meet the threshold for criminality'.
Labour's health spokeswoman, Marie Sherlock, asked the bodies if there were other reports of concern, with Ms Nugent stating there is another report on orthopaedic paediatric services still ongoing and that will be published in due course.
Eilish Hardiman, the former chief executive but now CHI'S strategic programme director, said there are 'reviews of individuals' that are going through HR processes within the organisation, but that the organisation 'would not be disclosing those'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Examiner
3 hours ago
- Irish Examiner
Number of festivals to have HSE's harm reduction initiative is halved ahead of drugs strategy review
The HSE harm reduction initiative will be at two festivals this year with officials saying they won't expand the programme any further pending a review. The operation of the HSE Safer Nightlife Programme at two festivals in 2025 compares to four festivals in 2024 and three in 2023. In a statement, the HSE said the programme cannot be expanded in its 'current format' and that it was due for a review in 2026, which will determine the 'next phase'. The HSE has recommended that changes to current policy 'should be considered' to 'improve engagement' with people using drugs. It said the HSE was hopeful that the next National Drugs Strategy, due later this year, will have 'clear recommendations'. It is understood that the number of festivals they work at depends on various factors, including the resources it has and the number of trained volunteers at their disposal. Priority is also placed on targeting the right audiences and ensuring health interventions are of high quality. The HSE statement said: 'The HSE will be at Ireland's largest festival Electric Picnic, and Ireland's largest dance event 'DX'." These events are at the end of August and September. The statement said: 'Back-of-house testing and outreach will be provided over three days of Electric Picnic, and two days of DX to support and identify risks for people who use drugs. The HSE is working with event organisers and gardaí to provide a health-led setting to ensure a safe space for people to discuss any difficulties or concerns they may have and to surrender drugs if they wish.' Back-of-house testing involves the authorities checking drugs that have been discarded by festival goers into official 'surrender bins' at the HSE tents and medical tents. Checks can also be conducted on drugs connected with a person brought to a medical tent. The HSE Programme operates with the formal agreement of An Garda Síochána as well as concert promoters. If scientists identify a trend of concern, the HSE issue alerts via social media, through volunteers and through digital billboards and signs. On potential expansion, the HSE said: 'In the current format, the HSE Safer Nightlife Programme cannot be expanded and is subject to review in 2026 to identify the next phase for this programme. 'The HSE recognises the need to expand the project to help identify drug trends on an annual basis. In its current format, 'back-of-house' analysis is not suitable for small venues such as pubs or venues, and it is not viable to expand to these settings. 'Policy amendments should be considered to identify how to improve this approach, remove service barriers and improve engagement with people who use drugs across Irish society in preparation for emerging drug threats. 'The HSE is hopeful that clear recommendations in relation to this area are included in the forthcoming drugs strategy.' Last May, the HSE warned users about new versions of the increasingly popular hallucinogenic drug, ketamine, and high-strength ecstasy pills, crystals, and powders.
The Journal
6 hours ago
- The Journal
Food company at centre of listeriosis outbreak was hit with two prohibition orders in recent weeks
BALLYMAGUIRE FOODS WAS served with two prohibition orders in the weeks leading up to a mass recall of ready meals and side dishes that it produces. These prohibition orders were part of the same investigation that ultimately led to the recall of over 140 food items this week. A prohibition order serves to prohibit the sale of an impacted product, either temporarily or permanently. Following these prohibition orders on 30 June and 18 July, a recall notice was issued to consumers and retailers. These recall notices were also listed on the FSAI website and an alert was sent to the media. Food items are often removed from shelves due to recall notices issued by the FSAI, but such notices tend to involve only certain batches. In a statement today, Ballymaguire Foods said that all of its products have been withdrawn and that the company has suspended all production. The company added that production at the affected facility 'will only recommence once the relevant authorities are satisfied'. The move comes after a total of 142 different ready-made meals and side dishes which are made and distributed by Dublin-based Ballymaguire Foods and sold in major supermarkets across Ireland were recalled due to the possible presence of bacteria called Listeria monocytogenes. Medical professionals are currently investigating the death of an adult with confirmed listeriosis. Nine cases of listeriosis had been confirmed as of Tuesday. Previous recall notices On 30 June , the FSAI issued recall notices on various branded Bacon & Cabbage Dinners produced by Ballymaguire Foods due to the possible presence of Listeria monocytogenes. These included meals produced for SuperValu, Tesco, and Centra. A HSE inspector was of the opinion that the various Bacon & Cabbage meals were 'injurious to health and unfit for human consumption' and directed that the ready meals be recalled. Advertisement Close to three weeks later, on 18 July , Ballymaguire Foods was again served a prohibition, with a recall notice being issued for various pre-packaged 'Turkey and Ham Dinners', which were sold in Centra and Supervalu. In a statement to The Journal , the FSAI said these two recall notices are 'part of the same investigation that is underway and which has resulted' in the recall of over 140 food items this week. A spokesperson for the FSAI added: 'As this is an on-going investigation no further details can be released.' 'Corrective actions' In a statement today, Ballymaguire Foods said it has appointed a public health expert to lead its response and that it is 'treating it with the utmost seriousness'. The spokesperson said the company is 'committed to doing everything necessary to responsibly and transparently address this, in full collaboration with the public health authorities'. As a precautionary measure, all Ballymaguire Food products have been withdrawn and it has suspended all production. The spokesperson said the company has 'taken corrective actions, including a full pharmaceutical-grade clean-down of the site' and that 'production at the affected facility 'will only recommence once the relevant authorities are satisfied'. It has also appointed Dr. Patrick Wall—former Chief Executive of the FSAI and former Professor of Public Health at University College Dublin—to lead its response team and review, including the implementation of any necessary enhanced procedures. 'We sincerely apologise for the concern this may cause,' said the spokesperson. 'Incidents of this nature are exceptionally rare and we are treating this with the utmost seriousness. 'We are acting decisively and transparently to protect public health which is of paramount importance to us.' Symptoms Listeriosis arises from an infection from Listeria monocytogenes bacteria. Symptoms can include mild flu-like symptoms, or gastrointestinal symptoms such as nausea, vomiting and diarrhoea. In rare cases, the infection can be more severe, causing serious complications. Some people are more vulnerable to Listeria monocytogenes infections, including pregnant women, babies, and people with weakened immune systems, including the elderly. The incubation period (time between initial infection and first symptoms appearing) is on average three weeks but can range between three and 70 days. Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal
RTÉ News
7 hours ago
- RTÉ News
Parents call on HSE to make breakthrough peanut allergy treatment available
Parents of children with severe peanut allergies are calling on the HSE to make a breakthrough treatment available in Ireland. Palforzia is a medicine for treating peanut allergy in children from one to 17 years of age. It has been authorised for use in the EU by the European Medicines Agency, but currently there is no planned timeline to roll it out in Ireland. It works by gradually exposing children to higher doses of peanut to help lower the risk of severe reactions, including anaphylaxis. This method is called oral immunotherapy. There are more than 20,000 children in Ireland living with a severe peanut allergy. The current approach is to avoid peanuts in the diet and carry emergency medication in case they are eaten. Some parents are now taking their children, at their own expense, to the UK, US or other European countries to access the Palforzia treatment. Catherine Dolan, from Greystones in Co Wicklow, is among a group of parents who want the HSE to make Palforzia available here. Her six-year-old son has a severe peanut allergy that puts him at risk of anaphylaxis. Ms Dolan said it creates a great deal of anxiety as the family navigates daily interactions. She has considered accessing the treatment abroad but said the logistics are difficult. "We've always had healthcare in our own country, and it does pose a risk when you go outside of the Irish system. I would consider it, we are talking about it, but I'd be really, really cautious about it," she said. Ms Dolan said she feels it is unacceptable that the treatment is available under the NHS in the UK, and other European countries, but not here. "We need to know when, and why. It has to happen. I'm balanced in my view - I know the healthcare system is really stretched, but I know the consultants are there, the care is there, and the expertise is there. We just need a national plan now to roll it out," she said. The HSE said it makes decisions on which medicines are reimbursed by the taxpayer on "objective, scientific and economic grounds". In November 2023, the National Centre for Pharmacoeconomics made a recommendation to the HSE that Palforzia "not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments". Professor of Paediatrics and Child Health in the Royal College of Surgeons in Ireland and Children's Health Ireland Dr Jonathan Hourihane said cost-effectiveness of medicines is usually calculated based on whether the amount of money needed to treat a condition can be recouped through demonstrated savings based on hospital bed use or emergency departments attendances. Dr Hourihane said this metric does not apply to peanut allergy. "This condition is a community-based disease characterised by anxiety and isolation, not by having to go to a hospital every two weeks. So, it's been unreasonably rejected. I think it's disappointing for us as a country, as a country that recruited children to get the licence for the product. And I think it's insulting to the families who have this condition," he said. Dr Hourihane said he attends international conferences and is told by allergy doctors that they are treating Irish children in the US, France, Italy and the UK, among others. He believes it is "a sign of desperation" that parents are willing to travel at their own expense for "care that they should be able to get locally". He added that Irish doctors are not supporting people to access treatment abroad because they are not involved in those programmes and cannot stand over them. Dr Hourihane said: "We are aware of children who've had to attend the emergency hospitals in Dublin having had allergic reactions during their treatment courses, and we don't know what they've reacted to because we're not involved. "So, I think it's putting doctors in allergy clinics in Ireland in a difficult position. They're having to treat children who are having complications of treatment being supervised remotely." Dr Hourihane believes the true impact of peanut allergies has been disregarded. He said: "It's not a trivial illness if you think your child might die tomorrow while you're at work. I think a fundamental problem with the way it's been evaluated is the impact hasn't been fully accepted in the way that families want it to be accepted. "As a clinician I find it frustrating and disappointing that the state-of-the-art treatments that we helped develop internationally [are not available here], and Ireland is a major international player in this area. We're now the laughing stock of the international allergy community." The HSE said the company that has applied to make Palforzia available through the HSE in Ireland has now paused the application until the end of this year. The HSE added that it "is committed to providing access to as many medicines as possible, in as timely a fashion as possible, from the resources available (provided) to it". "The HSE robustly assesses applications for pricing and reimbursement to make sure that it can stretch available resources as far as possible and to deliver the best value in relation to each medicine and ultimately more medicines to Irish citizens and patients," it said.
